Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : N-dihydrogalactochitosan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Swiss Group for Clinical Cancer Research
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial, conducted in collaboration with the Swiss Group for Clinical Cancer Research (SAKK), will assess the safety, tolerability and anti-tumor activity of IP-001 administered intratumorally following tumor ablation.
Brand Name : IP-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 10, 2020
Lead Product(s) : N-dihydrogalactochitosan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Swiss Group for Clinical Cancer Research
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?